Abstract Library

#3221 Independent administration of long-acting somatostatin analogues (SSAs) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET): Potential savings of increased uptake in the UK National Health Service (NHS)

Introduction: Lanreotide Autogel (LAN) and octreotide long-acting release (OCT) are long-acting SSAs used to treat GEP-NET. Only LAN is approved for independent (self/partner) injection, obviating need for in-person provider visits. Uptake of this option, already convenient for some patients, has accelerated in the UK amid the COVID-19 pandemic, with delivery modes reorganized in line with “COVID-19 rapid guideline: delivery of systemic anticancer treatments [NG161]” published for the NHS.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Harrow B, Cristeau O, Clay E, Francois C, Frankcom I,

Keywords: somatostatin analogues, GEP-NET, HEOR, covid-19,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,

#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues

Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jimenez Fonseca P

Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,

Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,

#2002 Pulmonary Function Test Physiology and Progression in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition characterised by a generalised proliferation of pulmonary neuroendocrine cells within the respiratory epithelium. Little is known of its affects on pulmonary function both at the time of diagnosis and prospectively.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Barlow J

Authors: Barlow J, Ryan D, Mansoor W, Howell M, Clayton N,

Keywords: Neuroendocrine, Cell, Pulmonary, Function, Hyperplasia, Pulmonary function, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, DIPNECH, Physiology,

#1002 Retrospective Study of MIBG Therapy for Phaeochromocytoma (PH) and Paraganglioma (PG): The Christie Experience

Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Salih Z, Fletcher K, Clay V, Manoharan P, Hawkins R,

Keywords: mibg,